about
The complexity of epigenetic diseasesChromatin signatures of cancerEditing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and PlasticityGenetic networks governing heart development.groHMM: a computational tool for identifying unannotated and cell type-specific transcription units from global run-on sequencing data.Epigenomics of macrophages.In search of the determinants of enhancer-promoter interaction specificity.Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.Transcriptional Enhancers: Bridging the Genome and Phenome.3D Chromosome Regulatory Landscape of Human Pluripotent Cells.Enhancer alterations in cancer: a source for a cell identity crisis.Conserved higher-order chromatin regulates NMDA receptor gene expression and cognition.Epigenetic targeting of activation-induced cytidine deaminase.Identifying transcriptional cis-regulatory modules in animal genomes.Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseasesExpression profiles of PIWIL2 short isoforms differ in testicular germ cell tumors of various differentiation subtypesTranscription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cellsGenomic Analysis and Isolation of RNA Polymerase II Dependent Promoters from Spodoptera frugiperdaNuclear myosin 1 contributes to a chromatin landscape compatible with RNA polymerase II transcription activation.Chromatin signatures at Notch-regulated enhancers reveal large-scale changes in H3K56ac upon activation.Intragenic Locus in Human PIWIL2 Gene Shares Promoter and Enhancer Functions.QuIN: A Web Server for Querying and Visualizing Chromatin Interaction NetworksTranscriptional Regulation of the Pancreatic Islet: Implications for Islet Function.A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression.Enhancer RNA-driven looping enhances the transcription of the long noncoding RNA DHRS4-AS1, a controller of the DHRS4 gene cluster.N-acetylaspartate catabolism determines cytosolic acetyl-CoA levels and histone acetylation in brown adipocytesDeletion of the Distal Tnfsf11 RL-D2 Enhancer That Contributes to PTH-Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in MiceQuantitative perturbation-based analysis of gene expression predicts enhancer activity in early Drosophila embryo.Inhibition of Interleukin 1β (IL-1β) Expression by Anthrax Lethal Toxin (LeTx) Is Reversed by Histone Deacetylase 8 (HDAC8) Inhibition in Murine Macrophages.Zic2 is an enhancer-binding factor required for embryonic stem cell specification.Epigenetics of hematopoiesis and hematological malignancies.Deciphering H3K4me3 broad domains associated with gene-regulatory networks and conserved epigenomic landscapes in the human brain.In the loop: promoter-enhancer interactions and bioinformatics.Abnormal levels of histone methylation in the retinas of diabetic rats are reversed by minocycline treatment.Computational schemes for the prediction and annotation of enhancers from epigenomic assays.Eukaryotic enhancers: common features, regulation, and participation in diseases.YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction.A time of change: Dynamics of chromatin and transcriptional regulation during nuclear programming in early Drosophila development.Progress and challenges in bioinformatics approaches for enhancer identification.Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomes.
P2860
Q26784416-FAA3CF0D-BDB9-4044-B14D-F75C6FCACA26Q27024162-5A5E05D6-AE5A-4148-A989-653F15FB770DQ28075883-39F62FC6-B835-4AEE-8CF6-DD67425EA9FAQ30367427-A01226DC-A49F-4D78-AFAE-EEB643D2074EQ30980309-29B51E02-6420-462B-AFBB-38B876C51428Q34372573-5A2EB69B-D9BB-4D8B-9AF3-D4A52FC6C136Q34435301-F23AE539-4834-4047-B3DC-363AE99C7458Q34489749-CDE3E8F3-12FE-4C87-BEE4-AEFEA739B505Q34502174-4E7AF1AD-BCE5-4182-8151-C79A3A091EF6Q34505845-365D09CE-9622-4ABB-8A3A-DBE361C95493Q34624854-A0CF8C7C-7CC1-48D8-8578-B9319245853CQ34644395-0F60E45C-729B-49A8-99E9-6133FB1F1935Q34831630-90FA626F-8C3F-4DC0-A8E5-CA770CB3A668Q35117066-3F4DB56C-6C8F-4E92-BF0E-55B1AB199355Q35340073-AB3BB542-06A4-49D4-A78E-BA93B9C4FC1AQ35407771-7349B0BC-2B37-4B4E-970B-FCFA36AF8852Q35530039-7ED9D125-CEC9-4131-A1AB-270FD2ED44FEQ35742800-9FB0EADA-FF7C-4078-8237-6021B9BBD2DBQ35800409-C0E51DD5-CA5E-487A-BD81-BB2182F5B389Q35991641-223B8DEA-CD3A-4FF4-A30E-8240A1F6EEB3Q36036138-86F3A74A-A045-4CD9-9BD5-0625A382CA20Q36059754-8D731C0F-6B5D-4601-A444-D8B359A63A0BQ36121381-EF95FB91-19D9-4111-A5C8-1138DEC64609Q36240398-0D63055C-4938-4A93-A2C9-2CDA3E6B2B3EQ36569927-68520943-5FC1-4F05-9624-3702AB3343E1Q36764814-8AC79A5F-573F-4B4B-8693-5F979D14483AQ36808470-A3877040-5FE6-48F1-937C-D161A5CDBBBFQ36879251-FA58E79A-2A6B-425E-A052-34F2857F63B2Q36884710-18C1A8D1-0879-46F6-8C08-2574946D8537Q37228941-5F6085C9-63CB-43A1-BCAF-A18FD6E0E705Q37343797-899BF866-99B2-49BE-A8B2-532ABF04C591Q37347653-086F2041-26B0-4D5B-9019-0C6005D0BB08Q37480563-0870C023-32C9-42A5-8115-E7C8674CC54DQ37719402-5D8FD4AA-D94F-4544-B01A-1AC50A5FC7AAQ38280813-F071B183-EBC0-4DCC-88C0-7EA32B210448Q38365224-C2FC9E2C-9D4F-439E-87F9-0FBB4AD56530Q38432867-C57EFE52-8228-48DE-9DD6-215FC9A445F2Q38534547-D4662982-B103-43CA-A303-5EAA507EA7A0Q38658633-13746A22-CD76-4BEF-98BB-B0D1355A240BQ38783184-6A98025E-2CED-4144-BC0B-74EFBD56A951
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Enhancer biology and enhanceropathies.
@en
type
label
Enhancer biology and enhanceropathies.
@en
prefLabel
Enhancer biology and enhanceropathies.
@en
P2860
P356
P1476
Enhancer biology and enhanceropathies.
@en
P2093
Ali Shilatifard
Edwin Smith
P2860
P2888
P304
P356
10.1038/NSMB.2784
P577
2014-03-01T00:00:00Z